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Executive Summary
ERA-NET Cofund on Biotechnologies (ERA CoBioTech), funded by the European 
Commission under the Horizon 2020 Programme, aims to maximise synergies 
between current mechanisms of biotechnology research funding in Europe, to 
discuss and demonstrate the benefits of a bio-based economy for society, and to 
maintain and strengthen Europe’s position in biotechnology.
Each ERA-NET has a set of administrative work packages. This document forms 
part of Work Package 6, Developing a Strategic Agenda for ERA CoBioTech, which 
is led by staff at the Biotechnology and Biological Sciences Research Council, UK. 
WP6 includes the development of a Work Programme on Responsible Research and 
Innovation (RRI), with three goals:
1. Ensure the strategic vision of ERA CoBioTech is responsive 
to ethical, economic, legal, social, technological and political 
aspects so that decisions about investments are made with a rich 
understanding of the implications for different actors.
2. Ensure that the ERA CoBioTech research community is supported to 
consider responsible innovation in a way that works in their specific 
contexts and creates public value.
3. Embed and share the lessons of trialling a new approach to 
responsible innovation.
To date there have been many calls for Responsible Research and Innovation (RRI) 
but little opportunity to learn from existing programmes to develop best practice 
approaches. Therefore, this document introduces the theoretical background to RRI 
and presents the results of an analysis of extant RRI programmes and qualitative 
interviews with key stakeholders in the governance of biotechnology with experience 
of the implementation of RRI. The insights from this analysis are presented in the 
form of four key lessons for research funders and researchers wishing to embed RRI 
into their programmes. The lessons are:
1. Commit to and value Responsible Research and Innovation: 
Recent analyses have drawn attention to system-wide challenges 
that provide space for RRI. It is therefore important that funders 
actively incentivise, make visible and value the time and effort for 
critical thinking about science-society relationships.
The final part of the document uses these lessons to create a series of 
recommendations and translates these recommendations into the context of ERA 
CoBioTech. The Agenda for Responsible Research and Innovation that the document 
develops is tailored to the context of an ERA-NET, which is not just a mechanism to 
foster scientific collaboration but also a means to encourage national and regional 
funding agencies to exchange skills and expertise by developing and managing joint 
research programmes. For this reason, the Agenda cuts across a broad range of 
activities within the programme. In particular, it identifies and outlines the practical 
content of four key tasks that ERA CoBioTech will embark upon over the course of  
its lifespan:
  Developing a Strategic Vision
  Building Research Consortia 
  Capacity Building Between Consortia
  Funding Evaluation and Measurement
2. Support tailored approaches: The most successful approaches to 
RRI appear to be highly tailored to the projects rather than using an 
externally imposed framework.
3. Find an appropriate form of integration: To date RRI has prioritised 
highly interdisciplinary modes of working. These are valuable but 
will not be suitable for all contexts.
4. Go beyond projects: Research into RRI will be more valuable if 
it can find ways to account for – and integrate with – governance 
spaces beyond the project level.
Strategic Priorities within Europe
Responsible Research and Innovation
Operationalising RRI in ERA CoBioTech
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1 Introduction and context to the report
ERA-NET Cofund on Biotechnologies (ERA CoBioTech), funded by the European 
Commission under the Horizon 2020 Programme, aims to maximise synergies 
between current mechanisms of biotechnology research funding in Europe to discuss 
and demonstrate the benefits of a bio-based economy for society, and to maintain 
and strengthen Europe’s position in biotechnology.
ERA CoBioTech was established in December 2016, will run for five years, and aims to 
combine fields of industrial biotechnology, synthetic biology and systems biology. It 
builds on a string of programmes around biotechnology that existed in FP6 and FP7, 
most directly ERA-NET Industrial Biotechnology 2, ERA-NET for Applied Systems 
Biology, and ERA-NET Synthetic Biology.
Each ERA-NET has a set of administrative work packages. This document forms 
part of Work Package 6, Developing a Strategic Agenda for ERA CoBioTech, which 
is led by staff at the Biotechnology and Biological Sciences Research Council, UK. 
WP6 includes the development of a Work Programme on Responsible Research and 
Innovation (RRI), with three goals:
The purpose of this document is to contribute to the development of the RRI 
work programme, explaining how ERA CoBioTech partners and consortia will 
take collective responsibility to ensure that the new knowledge, technology and 
innovation produced has public value and is more democratic, more environmentally 
sustainable and addresses more meaningful societal demands than may otherwise 
be the case. To this end, the report has five components:
1. First it will define the problem space, namely the relationship 
between science, technology and innovation and the creation of 
public value.
2. It will then outline the concept and current practice of Responsible 
Research and Innovation.
3. Next, it will present the results of qualitative interviews and 
desk research that analysed the implementation of flagship RRI 
programmes to date. The results of this work take the form of a 
series of ‘lessons’. 
4. The lessons will be transposed into actionable recommendations for 
those wishing to institutionalise RRI within a funding programme.
5. Finally, the report will translate these lessons and recommendations 
into a programme of work for ERA CoBioTech.
1. Ensure the strategic vision of ERA CoBioTech is responsive to 
ethical, economic, legal, social, technological and political aspects 
so that decisions about investments made with a rich understanding 
of the implications for different actors.
2. Ensure that the ERA CoBioTech research community is supported to 
consider responsible innovation in a way that works in their context 
and creates public value.
3. Embed and share the lessons of trialling a new approach to 
responsible innovation.
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2 The problem space: Science and public value
The most common justification for directing public funds towards research into 
science and technology is that doing so will produce benefits for societies. However, 
accurately predicting the benefits of research is incredibly difficult for the following 
three interconnected reasons1-10:
 
Science, technology and innovation do not develop in a 
linear manner with outcomes directly corresponding to 
the amount of money invested. Instead, development 
and distribution of benefits amongst social groups 
depends upon a wide range of social and situational 
factors such as who is involved, where the work is 
conducted, the kinds of oversight provided, and the 
types of intellectual property restrictions and other 
ownership arrangements in place. 
 
These contingencies mean that two seemingly similar 
technologies can have vastly different social and 
political consequences. For instance, two different litres 
of biofuels could be produced in very different ways: 
One using sugar cane in Brazil and blended at a large 
scale into European petroleum, another using waste 
biomass in a European country and consumed locally. 
These two biofuels would use different supply chains 
would have vastly different social, political and likely 
ecological consequences11,12. 
1.  
The time between initial funding (when potential 
benefits are envisaged) and when impacts can be 
identified is unpredictable and often of significant 
duration. Taken with contingency, this has two 
consequences. First, suggestions of future benefits 
usually occur in periods of hype and can be made in 
only generalised terms, which do not account for the 
multiple factors that will determine who benefits and 
how13-15. Second, it is challenging to retrospectively 
trace pathways from inception to impact in a 
comprehensive manner16,17.  
Genome Editing is a case in point here: despite offering a step 
change in scientific techniques, making predictable genetic 
modifications is still extremely challenging, which in turn limits the 
ability to know which of the vaunted applications may be viable and 
how the value they create will be distributed18-21. 
 
A final but important feature is that socio-
technical change is hard to reverse or 
correct retrospectively. This is because of 
‘lock-in’: new social behaviours become 
habitual, positions in a debate become 
entrenched, significant financial or material 
resources will have been invested, and new 
infrastructure may have been built (consider 
dependence on cars as the dominant mode 
of transport22). This means that it becomes 
harder – but not impossible (e.g. global 
use of CFCs) – to change the relationships 
between science and society as time passes. 
Photo by Shot On DJI on Unsplash
Moscow Institute of Physics and 
Technology GENOME ENGINEERING 
LAB 6 on flickr; CC BY 2.0
 jjmusgrove on flickr (CC BY 2.0)
1. Contingencies. 
2. Time lags. 
3. Lock-in. 
The challenge for policy makers: innovation governance
* E.g. compliance with ethics and biosafety procedures, intellectual property regimes (material transfer agreements and patents), environmental risk assessment and 
product-specific regulation, certification and labelling, as well as market dynamics. 
†	 For some examples of this mode of governance see Callon, Lascoumbes & Barthe (2009)39, Whatmore and Landström (2011)40 Stilgoe, Owen & Machnaghten{41 Smith et 
al (2017)42, BBSRC & EPSRC (2010)43 and Smith et al (Forthcoming)44.
  A question of choice: Where should finite resources (people, 
money, infrastructure etc.) be allocated and where not?
  A question of control: How should scientists, industrialists,  
policy makers, stakeholders and citizens foster science, technology 
and innovation so that they are beneficial for people and  
the environment?
  A question of representation: Under what conditions should 
decision making power be devolved to relatively small groups and 
under what conditions would they be improved by opening them up 
to broad groups of citizens, stakeholders and experts?
7
Erwin Schoonderwaldt on flickr; CC BY-NC-ND 2.0
The above features hint at how science, technology and society ‘co-evolve’ amongst 
networks (e.g. people and organisations). Co-evolution implies a number of  
questions for policy makers responsible for investing resources into scientific and  
technological development:
A wide range of governance mechanisms* help to shape the co-evolution of 
science, technology and society. What is needed, then, are more proactive forms of 
governing – and perhaps even talking and thinking about – the shared trajectories of 
science, technology and society†. These new modes of governing should account for 
contingency and look beyond prediction45. The 2007 European Commission report 
"Taking European Knowledge Seriously" makes a similar call, recommending that 
the EU move from risk-governance to innovation-governance, i.e. from narrowly-
construed concerns with safety to governing for broader societal goals1. Because 
they are inherently upstream, research funding programmes are one key point at 
which this should happen. 
In the context of ERA CoBioTech, answering these questions means engaging with a 
broader debate about the kind of Knowledge-Based Bio-Economy that programme 
partners and consortia are aiming to foster, and deciding who should be involved 
in the discussions that influence decision making and research. But what would 
innovation governance look like in practice? The objective of this review is to develop 
a set of recommendations for best practice within a research funding programme to 
help address this question.
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3 Responsible Research and Innovation
Responsible Research and Innovation (RRI) is an innovation governance process 
that addresses current gaps in the established approaches described above. The 
concept was first articulated (as Responsible Innovation) by Richard Owen and 
partners at the EPSRC as an attempt to move beyond risk-based regulation in the 
field of nanoscience46,47. This was later embellished with cases of solar radiation 
management, also in the context of EPSRC-funded research48,49. It has  
subsequently been expanded to sit across the breadth of EPSRC’s doctoral  
training funding mechanism. 
A diverse set of programmes and projects are collected under the term ‘Responsible 
Research and Innovation’ and distinct but intertwined policy developments have 
resulted in at least two dominant frameworks. The work between Owen, Stilgoe, 
Macnaghten and the EPSRC resulted in the 'Anticipation, Inclusion, Reflexivity, 
Responsiveness' (AIRR) framework, articulated in a policy statement by the research 
council. The AIRR framework explicitly builds on the networked nature of science, 
technology and innovation: such processes are often distributed over extended 
timescales, across multiple spaces and between different actors, which poses 
challenges when allocating responsibility. A key goal of the AIRR framework is to 
act as a social innovation that instils a collective ‘care for the future’ across science, 
technology and innovation networks, asking those involved to:
1. consider the future directions of their work and its potential 
plausible consequences (Anticipate);
2. open up and seek out a broad range of voices, be they citizens or 
experts in decision making (Inclusion);
3. reflect on the significance of those directions and consider 
alternative approaches (Reflexivity); and
4. integrate the outcomes of this process into their own  
practices (Responsiveness).
Crucially, this conception of RRI requires redistributions of responsibility and 
potentially new roles and new institutions. For instance, one recent report by the 
British Academy and Royal Society examined ‘Data Management and Use’ in relation 
to the concept of Responsible Research and Innovation, and recommended the 
creation of a new ‘Stewardship Body’ to oversee the development of new data-
intensive technologies 50. Similarly, discussions about Gene Drive technologies, 
which are able to propagate naturally unfavourable traits through populations of 
organisms, has led to calls from research funders for the design of new governance 
mechanisms, such as ‘Funder Forums’51. In this vein, one commonly identified and 
key issue is that of agenda setting and research programme design52-54.
In parallel to these developments, policy makers in the European Commission have 
given political currency to the discourse of responsibility55. Over a roughly three-year 
period, an EC programme of Responsible Research and Innovation was developed, 
articulated in policy documents56 and built into the EC's flagship Research and 
Innovation Agenda, Horizon 2020. The European Commission framework differs 
to EPSRC’s and articulates RRI in terms of five ‘keys': societal engagement, gender 
equality, open access, science education, and ethics compliance. 
H2020’s version of RRI operates at a scale beyond AIRR, in part because it is a 
complete replacement of a wide-ranging Science in Society Research Programme. 
The ‘keys’ can be viewed as a means to achieve this scale and function by adding 
momentum to pre-existing governance activities. However, in doing so they are likely 
to trade-off some of the socially transformative capacity that EPSRC aims at. While in 
practice these are distinct policy frameworks, some have suggested that the five keys 
can provide a useful entry point for those new to the idea of responsible innovation 
in science and technology – a place to begin discussion that can then move on to 
grappling with deeper system change and social learning that AIRR implies57.
Plurality and RRI
In practice H2020’s approach to RRI has 
resulted in a multitude of projects all 
attempting to articulate a concept of 
responsible innovation that is trans-
national and suited to many different 
contexts58. However, these projects 
come from different national contexts 
and different disciplinary positions, 
meaning that the approaches that 
each RRI programme or project takes 
are often nationally sensitive, having 
evolved with the respective research 
cultures48,55,59. For instance, the AIRR 
framework has also been adopted by 
the Norwegian Research Council in its 
Biotek2010, Nano2021 and IKTPLUSS programmes*. In the United States, centres 
developed around the notion of Anticipatory Governance and Real Time Technology 
Assessment as part of the National Science Foundation National Nanotechnology 
Initiative60. RRI work in the UK is rooted in nanoscale science, geoengineering and 
synthetic biology, building on concepts such as ‘Upstream Engagement’.  
Patrick Lauke on flickr; CC BY-NC-ND 2.0
* See https://digitallifenorway.org/gb/responsibility (accessed 23/07/2018) 
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† See https://www.nwo.nl/en/research-and-results/programmes/responsible+innovation (accessed 23/07/2018) 
‡ Argentina, Belgium, Estonia, France, Germany, Holland, Israel, Italy, Latvia, Norway, Poland, Portugal, Romania, Russia, Slovenia, Spain, Switzerland, Turkey, and the UK. Although note not every funder takes part in all funding calls.
✣ https://www.kowi.de/Portaldata/2/Resources/fp/Report-ERA-NET-FP6-H2020.pdf (Accessed 23/07/2018)
1. Should the approach be bottom-up or top-down?  
Is RRI conceptualised as a process of (site-specific) mutual learning 
and capacity building or as something to be implemented top-down 
and evaluated through common indicators and metrics49,58?
2. What is the most appropriate site to focus on? 
Are scientific processes and technology development seen as sites 
for RRI or are they protected spaces, leaving RRI-related work 
to focus solely on the downstream implications of knowledge 
and technologies? If science and innovation are to be shaped, 
then how should this happen and who should be involved? For 
example, should it involve work in the laboratory, in the design of 
a research agenda, or in the commercialisation process, by expert 
representatives or through direct citizen participation?
3. Is it best to work with existing innovation systems or foster 
alternative ones? 
The goal of Responsible Research and Innovation is to foster public 
value from science, technology and innovation. However, some 
question the feasibility of such a goal within existing dominant 
regimes of economics and intellectual property ownership. Instead 
they suggest that alternative models of innovation developed 
with different economic frameworks, such as frugal innovation or 
grassroots innovation, may be better means to the same goal63-66.
Implications for ERA CoBioTech
And programmes such as The Netherlands’ Responsible Innovation Research 
Programme (NWO-MVI)†, mobilises a community that draws on concepts such as 
Constructive Technology Assessment and Value Sensitive Design61.
An analysis of all these approaches reveals three common but often implicit tensions 
surrounding the implementation of RRI62:
1. Engagement with users and/or publics;
2. Attention to the social context of the scientific research and its 
proposed uses;
3. Acknowledging the political dimensions of choices around science 
and technology, and seeking to establish processes to increase 
transparency and accountability for decisions;
4. Incorporating these analyses and activities in 'real time', while they 
are still able to have an influence, rather than after research and 
commercialisation; and
5. A desire to operate across multiple spaces within an innovation 
system, i.e. beyond the level of individual scientific projects.
Drawing attention to diversity of approaches to RRI and the implicit tensions in policy 
and practice is significant for ERA CoBioTech in two key ways. 
First, there is no one single ‘right’ approach to RRI; rather there are many national 
traditions and a plurality of methods that allow questions to be asked about the 
relationship between science, technology and public value. However, all the 
approaches outlined above commonly focus on the following shared goals55,62,67:
Thus, the approach to RRI outlined in the final 
section takes these five goals as points of departure 
and seeks to mobilise, rather than impose on, pre-
existing work and expertise. In practice this means 
not requiring that ERA CoBioTech commits to one 
specific version of RRI. Instead, institutions should 
be aware of the substantive differences in potential 
approaches and build on the lessons for best 
practice described in the following section.
Second, ERA-NETs are not just a mechanism for 
collaboration amongst scientists; they are equally 
intended to encourage national and regional 
funding agencies to exchange skills and expertise 
by developing and managing joint research 
programmes. ERA CoBioTech incorporates 22 
funding partners from 19 countries‡. Past reviews 
of the ERA-NET schemes have emphasised the 
heterogeneity of funders and their respective 
legislators. There are relevant distinctions to be 
made between respective funding sizes, preferred funding styles, administrative 
organisation and even the funder’s relationship to H2020✣. In the context of ERA 
CoBioTech’s Agenda for Responsible Research and Innovation, it is therefore 
important to be aware that knowledge exchange between research funders matters 
almost as much as between funded researchers and to keep in sight the complexities 
involved in managing and administering an ERA-NET. The next section provides a 



















4 Learning from past experience with RRI
Despite an increase in the number of RRI programmes in the last few years, there 
has been little systemic learning with implementable policy recommendations. This 
section develops a series of cross-cutting lessons for the ERA CoBioTech programme 
from experiences within a range of flagship RRI programmes (see table one). 
Targeted specifically towards research funders and programme managers, these 
lessons are based on telephone interviews, analysis of accompanying grey literature, 
and a series of published articles on researchers’ experiences in the field. More 
methodological detail is provided in Annex 1.
Funder Programme Description
EPSRC, BBSRC & MRC Synthetic Biology Research Centres
A series of large scale centres funded through the UK Research Councils' 'Synthetic Biology for 
Growth' strategic investment. A pre-requisite for funding was that each centre contained substantive 
Responsible Innovation components.   
European Commission Horizon 2020 Framework Programmes
One of the largest 'ethics, legal and social' programmes in terms of financial investment. A shift in 
conceptualisation from 'science in society' to 'responsible research and innovation' occurred at the start 
of the H2020 funding round in 2014.
Genome Canada 
& Genome British 
Columbia
Genomics and its Ethical, Environmental, 
Economic, Legal and Social Aspects 
(GE3LS) Programme
Two not-for-profit catalyst organisations intended to produce genomic-based applications. The GE3LS 
programme runs in parallel to funded scientific and translational research.
NSF & Department  
of Energy
Synthetic Biology Engineering Research 
Centre (Synberc) and Joint Genome 
Institute (JGI)
Large research centres in the United States. Synberc had significant social science and ethics 
components. JGI introduced social and ethical review for scientific proposals.
iGEM Foundation International Genetically Engineered Machine Competition (iGEM)
An annual synthetic biology competition, inaugurated in 2003. The foundation places an emphasis on 
'Human Practices' being integrated into the scientific projects.
Research Council of 
Norway Digital Life Programme and BIOTEK2021
Two large flagship biotechnology investments, each of which required responsible innovation 
components as pre-requisites for funding.
University of Tokyo Science Interpreter Training Programme An emerging Japanese programme, seeking to build capacity for novel 'ELSI methods' in genomics.
TABLE 1: PROGRAMMES REVIEWED AS PART OF THIS AGENDA
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Lesson 1: Commit to and value responsible research and innovation
A core aspect of RRI is enabling scientists and engineers to ask questions about 
the social and political dimensions of their work and integrate the answers into 
their broader research trajectories. Many interviewees strongly argued that this is 
significantly influenced by the value that research funders confer on such processes. 
For instance, while the iGEM competition* locks entrants into quite a narrow 
definition of 'problem' (something 'out there' in the world) and 'solution' (synthetic 
biology technology), it has fostered and supported ‘Human Practices’ as a valuable 
approach by integrating it into the award structure of the competition. A team 
cannot achieve a gold medal award without showing effective and meaningful work 
in Human Practices68. The corollary of this point is that there is an onus on research 
funders to incentivise, make visible, and value the time and effort for critical thinking 
about science-society relationships.
Four lessons for best-practice RRI
Lesson 2: Support tailored approaches
An overarching lesson from both literature and interviews is that, if successful, the 
responsible innovation components of projects can provide rich explorations of 
the core complexities and uncertainties of a project and allow project researchers 
to reflect on the desirability of its goals. This means that project team members 
are likely to derive the most value from responsible innovation research if it is 
tightly interwoven with the natural science/engineering research so it can address 
substantive issues that this research raises. Thus, rather than RRI components being 
imposed uniformly by an external RRI Framework or checklist, project teams should 
be able to take an active role in identifying questions that they consider relevant to 
their project. External frameworks, such as the EC’s Keys and EPSRC’s approach, 
have value because they can provide useful entry points for broad concerns, but 
ideally collaborative project teams should be able to identify the specific research 
questions and approaches that fit with their project’s national, organisational, and 
disciplinary context.
Lesson 3: Find an appropriate form of integration
Ideally, Responsible Research and Innovation projects should investigate relevant 
ethical, social, political and environmental dimensions in real-time rather than 
analysing impacts post-facto, and as a core part of the project’s activities rather than 
as an add-on. An effective way to do this is through collaborative, interdisciplinary 
modes of working across the natural and social sciences and humanities†. It is 
important to note that while interdisciplinary modes of working can be fruitful, they 
can also come with increasingly well-documented ambivalences69,70. For instance, 
collaborative modes of working may take a disproportionate amount of effort to 
initiate, can be professionally precarious for early career researchers, and can come 
with high emotional burdens, especially when power and the ability to define roles 
rests with a single principal investigator (PI). Including interdisciplinary aspects 
as an after-thought to a grant may exacerbate such problems. While successful 
RRI research likely requires collaboration across natural and social sciences 
and humanities, the form of this collaboration should be determined by all the 
collaborators involved.
Lesson 4: Go beyond projects
The literature developing Responsible Research and Innovation approaches 
consistently argues that system-wide dynamics should be taken into account. 
Prominent scholars have argued that the failure to take such a multi-scalar 
perspective has resulted in biases and significant gaps in analyses of emerging 
science and technologies71,72. This means that individual scientific projects and 
technological objects are not the sole site of inquiry for RRI research. That said, 
the vast majority of funding devoted to responsible innovation practices is 
allocated through time-limited and discrete funding at the project level, and it 
is understandably daunting to address systemic issues – such as national and 
international funding priorities or intellectual property regimes – within an individual 
project. ERA CoBioTech funders can be champions for best-practice by helping to 
connect work across projects and enabling RRI research beyond the lab.
* The iGEM competition is an annual competition in synthetic biology in which approximately 300 undergraduate and postgraduate teams compete to design, construct and characterise new synthetic biology ’parts’. The annual ‘jamboree’ is one of the largest synthetic biology conferences in the world.
† Such an approach is represented by terms such as ‘adjacency’, ‘parallel research’, ‘experimental collaboration’, or ‘intervention’.
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5 Recommendations for best practice RRI
How would these lessons play out in practice? Here, we translate them into 
actionable recommendations, applicable to the context of ERA CoBioTech. The 
fourteen recommendations, overviewed in table two, are structured according to five 
key activities and three key groups of actors. 
Recommendation Activity Audience
Treat Responsible Research and Innovation components as research. Overarching recommendation All
Communicate the commitment to RRI early in the funding cycle and 
provide pre-application support to understand its goals. Developing funding calls Funders
Ensure any RRI components are context-specific and detailed.
Try to build a ‘conception to grave’ work package.
Researcher Equivalence.
Resource accordingly.
Building consortia applications and 
conducting research
Project consortia
Review RRI components thoroughly and appropriately.
Assess RRI as more than an indicator of 'impact'.
Allow for emergent approaches to investigation.
Don’t be overly prescriptive.
Evaluating funding applications Grant reviewers/Funders
Help make connections.
Provide resources to connect RRI work across projects.
Support research into sites beyond the lab.
Capacity building Funders Project consortia
Develop effective evaluation methods. Grant monitoring and programme evaluation Funders
TABLE 2: RECOMMENDATIONS INFORMING ERA COBIOTECH’S AGENDA FOR RRI WITH ASSOCIATED ACTIVITIES AND AUDIENCES
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Overarching recommendation: Treat RRI components as research
There are contrasting opinions about the status of RRI 
components within research projects. Many of the 
EC RRI projects are funded as ‘support actions’ rather 
than ‘research’, despite the fact that social scientists 
and other RRI practitioners are often professional 
researchers. Not treating RRI as ‘research’ can create 
confusion about the roles that component leaders are 
meant to take and can produce superficial work.
We recommend that ERA CoBioTech treats any RRI 
component as an engaged form of research. While 
there will likely be cross-over between this component, 
communication and outreach, and impact, such 
an approach will ensure that the RRI work is substantive. This means that RRI 
components require personnel with appropriate expertise and are not primarily 
about demonstrating a project’s benefits for stakeholders. Ideally RRI components 
and the wider project will work towards an important issue of shared interest.
Recommendations for the development of funding calls
Communicate the commitment to RRI early in the funding cycle and provide 
pre-application support to understand its goals.
Our analysis points to the importance of close 
alignment between the natural and social science 
and humanities components of funded projects. 
In order to facilitate this, the requirements for RRI 
components should be articulated to ERA CoBioTech 
applicants as early as possible whilst acknowledging 
that such a requirement may be novel for many 
applicants. The commitment should therefore be 
accompanied by support materials such as the briefs 
produced as part of this contract. Additional support 
through workshops, online courses, etc. is welcomed.
Ensure any RRI components are context-specific and detailed.
For RRI-related research to be substantive, it must be tailored to the project. We 
strongly recommend that RRI components be developed in association with the core 
project proposal, rather than on the periphery. As discussed below, this does not 
mean that all applications must detail the full specificities of the RRI research, but it 
does mean that applications must demonstrate a plan for developing this agenda. 
For example, if a project contains a discrete WP on RRI, the minimum requirement is 
that appropriate experts (e.g. social scientists) are identified.
Recommendations for building consortia applications and conducting research
Try to build a ‘conception to grave’ work package.
To ensure close alignment between the natural and social science and humanities 
components of funded projects, the RRI components should be discussed and set 
by project members early on in the process and continue through the life cycle of 
the project. For projects with extended timeframes, the precise nature of the work 
package will likely vary over time.
Researcher equivalence.
While the RRI components will often represent 
a smaller than average portion of an overall 
ERA CoBioTech project, it is crucial that 
the RRI-related staff are not considered 
subordinate or wholly at the service of other 
project elements. RRI should be a context 
specific and collaborative process, and in order 
to achieve this it is vital all collaborators have 
continuous input into the life of the project 
as a whole. Project teams should consider 
including RRI expertise in advisory boards and, 
where appropriate, RRI lead researchers as 
co-PIs. Such actions are indications that these 
components are taken seriously.
Kate Ter Haar on flickr;  
CC BY 2.0
Photo by Neil Thomas on Unsplash
Photo by Christian Joudrey on Unsplash
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Resource accordingly.
Research funders (ERA CoBioTech partners) should set appropriate baselines for 
financial resources dedicated to RRI activities and research. This could be either as a 
set amount for types of activity or as percentage of the overall budget and will help 
to ensure not only sufficient resources for RRI-related research, but also provide 
flexibility for the RRI programmes of work to change over time. Advocating for 
investigative flexibility implies a need for budgetary flexibility to ensure the ability 
to respond to changes in the life of the project and to collaborations that may arise 
over the course of the programme. Arguably, this is also the case for the natural and 
physical science components of projects42.
Recommendations for the evaluation of funding applications
Review RRI components thoroughly and appropriately.
If funders and applicants are to take seriously the 
commitment to examining the social, ethical, political, and 
environmental dimensions of projects, and if related RRI 
work packages are expected to contain substantive work 
with budgetary commitments, then they must be reviewed 
effectively. At a minimum, this means that grant reviewers 
must be capable of reviewing the social sciences and 
humanities aspects of grants. This likely means that two social 
scientists and/or humanities scholars will be required to sit 
on the review panel, with the power to request changes to 
relevant portions of applications.
Assess RRI as more than an indicator of 'impact'.
Interviewees explained that grants were significantly better when the RRI-related 
components of applications were reviewed in the same manner as the scientific 
components. In practice, RRI is currently assessed as part of the "impact" of a project. 
We recommend that RRI form part of a broad understanding of excellence and 
implementation that encompasses societal engagement and inclusion, enabling 
different kinds of innovation. This means that comprehensive RRI components 
should be visible in other aspects of an application's evaluation. Similarly the panel 
should use evaluation criteria for ‘excellence’ (see Annex 2) that are broad enough to 
not penalise placing RRI at the heart of the project.
Allow for emergent approaches to investigation.
Funders asking for projects to include RRI components should be open to unexpected 
outcomes, both from the RRI-related research and the project as a whole. A 
successful application may not identify what specific issues will be addressed in 
its RRI components, but rather detail the process through which such issues will 
be identified. However, if such an approach is taken, it is vital that the application 
outlines the appropriate methods, provides appropriate resources, and explains how 
emergent issues will be identified and explored as part of the project. 
Don’t be overly prescriptive.
In practice, allowing for bottom-up RRI practices and research means that there 
can be no hard and fast rules about the precise nature of RRI at a programme level. 
This is particularly the case for the ERA CoBioTech programme, which encourages 
involvement beyond the EU-15, thus involving a wide range of social, environmental, 
political, and economic contexts, and attendant concerns and questions. Unlike the 
Dissemination and Communication component of ERA CoBioTech projects, there 
is not a specific template for RRI-components. Subjecting the spaces created for 
science–society interactions to a tight framing undermines the creativity and value of 
such settings. Building in such flexibility is not an argument for vagueness; specificity 
regarding the methodological approaches and general research questions are 
arguably as – if not more – important. Many of the concerns that tight prescription 
seeks to allay can be tempered by the overarching recommendation, above, and by 
requiring procedural rigour.
Recommendations for capacity building across the ERA CoBioTech programme
Help make connections.
Interviewees stressed the importance of funders taking 
an active role in making connections between social and 
natural scientists. For example, the ERA CoBioTech funders 
could host "match-making" workshops at which natural 
scientists could meet social scientists whose interests align 
with theirs. Establishing such relationships before or in 
the process of developing a grant application, rather than 
writing the grant and then looking for RRI experts to add 
on, makes it more likely that RRI components of the grant 

































Provide resources to connect RRI work across projects.
ERA CoBioTech will fund a variety of projects across Europe and beyond. If many (if 
not all) of these projects have associated RRI work, this represents an opportunity 
for unique learning. We recommend that funders help coordinate networking across 
the projects and knowledge exchange between the experts involved in RRI work. This 
represents an opportunity for not only identifying and sharing best practices, but also 
conducting research.
Support research into sites beyond the lab.
The primary site of inquiry for RRI research needn’t be restricted to the research 
project. Sites at different levels, such as funders, regulators, and international 
governance fora, may well be relevant to the questions and concerns related 
to a project. Indeed, there are many relevant system-wide insights in research 
management that are traditionally excluded from RRI practices but included in other 
national approaches, such as anticipatory governance or upstream engagement73-77.
Recommendations for grant monitoring and programme evaluation
Develop effective evaluation methods.
RRI should be more than just an initial hurdle to gain access to research funds; 
when considered as substantive in its own right it must also be considered as part 
of evaluating a project’s success. Adequate evaluation frameworks do not yet seem 
to exist. We therefore recommend that ERA CoBioTech take steps to develop such 
an approach, based on key principles derived from our interviews and literature, 
and likely combining qualitative and quantitative approaches. For instance, a 
prominent European Science Foundation report recommends a framework with the 
following features: qualitative analysis and broad quantitative indicators; a focus 
on process rather than output; and a commitment to a period of experimentation 
before finalising the approach taken3. Developing an evaluation framework would 
demonstrate ERA CoBioTech’s commitment to engaging with questions of  
social value.
Photo by patricia serna on Unsplash
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6 Outlining ERA CoBioTech’s approach to Responsible Research and Innovation
This report has introduced the context of ERA CoBioTech, the theoretical 
underpinnings of Responsible Research and Innovation and articulated a set of cross 
cutting lessons from previous science, technology and innovation programmes. In 
this part of the report we apply these insights to the ERA CoBioTech programme’s 
Agenda for Responsible Research and Innovation (ARRI).
As discussed, there is no single right way to ‘do’ RRI. Instead, there is a broad range 
of RRI-related research and engagement activities able to explore the political, 
economic, environmental and social dimensions of science and technology and 
to provide relevant, diverse knowledge and perspectives to inform research and 
innovation. This pluralistic approach to RRI is important because ERA CoBioTech 
spans several Technology Readiness Levels (TRLs). In the context of a lower TRL, RRI 
may mean providing a substantial role for citizens in setting a research agenda but 
it might also mean seeking the input of experts outside a normal area of technical 
expertise by including social scientists, sociologists and/or economists to project 
advisory boards44,78.  These approaches would be relevant for higher TRLs, but so 
would more formal and discrete approaches to examine and analyse the impacts of  
a technology.
Thus, ARRI aims to provide ERA CoBioTech with a framework that defines a broad 
arena for RRI’s meaning within the programme, rather than narrowly dictating what 
RRI research and engagement should look like. Given the complexities of the ERA-
NET programme within H2020 and the range of national funders, we have designed 
an ARRI for ERA CoBioTech that focuses on four key tasks spanning the breadth of 
the programme, i.e. that focus both on the project level and the operational work of 
ERA CoBioTech: 
1. Developing a Research Agenda
2. Research Consortia 
3. Capacity Building Between Consortia
4. Funding Evaluation and Measurement
The limits of this approach
The boundaries of ERA CoBioTech’s approach to Responsible Research and 
Innovation deserve attention. Addressing questions of value in relation to science, 
technology and innovation is necessarily a collective endeavour and requires the 
input of many different actors in many different sites. ERA CoBioTech funders, the 
scientists and the partners that they support represent one small portion of the 
actors involved in the creation of value.
Many public debates about biotechnology directly question the dominant forms 
of intellectual property regimes and ownership79,80 and in arenas outside ERA 
CoBioTech, important experiments are on-going to explore alternative models*. This 
Agenda for RRI does not mandate or even recommend particular forms of intellectual 
property (e.g. patent pooling, open MTA) or data sharing. Due to the complexity 
of national priorities, this is not a matter for ERA CoBioTech to determine.  Of 
course, research consortia may choose to work on alternative IP as part of the RRI 
components of their projects and they may do so collectively. Indeed, possible 
indicators of success for the implementation of this Agenda would be that future calls 
are able to respond to the changing needs of the relevant communities over time, 
and that a series of shared issues and methods are addressed collaboratively over the 
course of the programme.
* See the BBSRC-funded ‘OpenPlant Synthetic Biology Research Centre’, which aims to develop open models of innovation. https://www.openplant.org (Accessed 23/07/2018).
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Task one: Developing a strategic vision
Developing new ways to strengthen the connections between research and 
innovation agendas and citizens has long been suggested as instrumental in the 
creation of public value7,81-84.  For instance, recent analyses have demonstrated 
mismatches in the priorities of members of the public and technologists in relation 
to agriculture and health73✝. In arenas outside ERA CoBioTech, experiments are on-
going to explore alternative modes of priority setting‡. Further, widespread public 
participation has been called for when determining the ‘missions’ of the European 
Commission’s forthcoming ‘Mission Oriented’ Framework Programme85✣. However, 
to date there have been relatively few documented attempts to open up agenda 
setting in biotechnology research programmes86.
In practice: Trialling a new approach to agenda setting in ERA CoBioTech
Incorporating the present RRI subproject into ERA CoBioTech's Strategic Vision work 
package is in itself a commitment to ensure that RRI shapes the research agenda. 
However, in practice the programme will also trial an approach to developing a 
Strategic Vision that integrates RRI. In particular:
1. It will draw upon a rapid stakeholder mapping approach, previously developed 
with BBSRC staff and deploy it to identify relevant participants in a ‘strategic 
vision’ workshop. 
2. Social scientists will co-design workshop tasks, focused around: 
a. identifying present and missing stakeholders;
b. mapping important funding programmes and technological developments;
c. reflecting on the key questions and purposes driving ERA CoBioTech;
d. interrogating gaps and assumptions in the above dimensions and considering 
broad notions of success. 
3. WP6's 'Strategic Vision' will be informed by the workshop and developed in 
partnership with social scientists.
† Specifically for health in terms of global disease burden vs. biomedical research priorities. For an introduction see https://www.theguardian.com/science/political-
science/2018/mar/16/who-benefits-from-biomedical-science, https://www.natureindex.com/news-blog/drug-research-priorities-at-odds-with-global-disease-toll and https://
observatoriosociallacaixa.org/en/-/responde-la-investigacion-a-las-necesidades-de-salud (Accessed, 23/07/2018).
‡	 See e.g. Nesta, ‘Everyone Makes Innovation Policy’ Project, which has funded five experimental approaches to research agenda setting. https://www.nesta.org.uk/blog/
announcing-the-everyone-makes-innovation-policy-programme-grantees/ (Accessed, 23/07/2018).
✣ https://ec.europa.eu/info/node/71880 (Accessed, 23/07/2018)
Mostafameraji [CC BY 4.0 (https://creativecommons.org/licenses/by/4.0 ]
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In practice: Programme-wide workshops
A first step to building capacity will be to convene workshops specific to Responsible 
Research and Innovation over the life of the programme. These will be developed 
and implemented by external facilitators in collaboration with consortia members to 
address shared topics of interest or develop cross-cutting methods for RRI. 
The workshops will be held as side-events to pre-existing cross-consortia meetings, 
namely the kick-off meeting for each funding cohort and project update meetings 
(mid-term and final seminars). Projects must therefore build attendance costs for 
two participants into their budgets.
In addition to these actions, future calls may specify particular areas of focus based 
on past experience within the ERA CoBioTech portfolio.
Task three: Capacity building between consortia
It is now common for funders to 
require Responsible Research 
and Innovation components in 
research proposals. However, the 
interdisciplinary collaborations that 
facilitate successful research in this 
area are fragile and the nature of 
project funding (e.g. time-limited, 
tightly-allocated) can make it 
challenging to take the experience 
generated in one project and transfer 
it to another.
Delivering ERA CoBioTech funding 
in tranches, and to consortia that are 
expressly built to collaborate across 
Europe, presents an opportunity to 
build reflective and methodological 
capacity across the programme. ERA 
CoBioTech funds diverse project consortia but there are similarities in the goals they 
aim to achieve, the methods they employ, the topics they address and the issues 
that members encounter. To begin to foster learning across the programme, ERA 
CoBioTech funders will provide activities and resources explicitly intended to build 
shared learning across the ERA CoBioTech programme.
Task two: Consortia-led research
ERA CoBioTech will facilitate the development of interdisciplinary consortia that 
develop research plans with a clear societal need. This research is highly specialised, 
meaning that consortia may be best-placed to understand and address issues as they 
emerge. Thus, each call in ERA CoBioTech contains a requirement that consortia 
build-in and appropriately resource on-going research and consideration of the 
ethical, social, environmental or political (etc.) dimensions of their work. Such an 
approach — that includes disciplines with expertise to address questions that ‘go 
beyond the technical’ — is a well-established approach to Responsible Research 
and Innovation. The research funded through ERA CoBioTech is diverse. There 
is not, therefore, a one-size-fits-all approach. ERA CoBioTech will adopt a broad 
understanding of what an appropriate topic for Responsible Research and Innovation 
is and what the appropriate methods are. Clear guidance on both the process and 
how it is to be evaluated will be provided with each funding call.
In practice: Integrating and assessing Responsible Research and Innovation 
within funding calls.
In practice, this task must be led by consortia members. However, ERA CoBioTech 
funders will provide support in the following ways:
1. Clear guidance explaining the expectations and assessment of Responsible 
Research and Innovation within ERA CoBioTech funding calls, including the forms 
of financial support available from each national funder (These are provided in  
Annex 2). 
2. Clear guidance regarding the evaluation of Responsible Research and Innovation 
within the application review process. 
3. Specific expertise relating to Responsible Research and Innovation will be 



































Task four: Developing appropriate measures of success
The final task that this agenda prioritises is research funder decision-making. 
We have already discussed funding calls, but one further activity relates to grant 
evaluation and portfolio analysis — activities that are used to analyse and evidence  
whether a programme has been successful. These evaluative processes are extremely 
important in shaping research because they indicate to scientists what outcomes are 
valued, such as IP, collaborative papers, grant income, and/or knowledge. 
However, there remains considerable uncertainty regarding the most appropriate 
ways to capture the outcomes and added value of ERA-NET programmes, including 
how to evaluate Responsible Research and Innovation. ERA CoBioTech funders will 
therefore develop an approach that effectively captures and prioritises broad forms 
of value-generation across the portfolio.
ERA CoBioTech is uniquely placed to pioneer this kind of work for several reasons. 
The programme is in its first stages of operation, and the indicators for evaluation 
of the first round of funded projects are still under construction. It is also a multi-
national, multidisciplinary programme with an explicit commitment to include RRI 
in the project specifications and its remit is to fund new and emerging scientific 
research that moves from one TRL level to another, focused on producing outcomes 
with potentially high impact on society.
In practice: piloting a novel form of programme evaluation
ERA CoBioTech is currently developing a series of evaluation criteria for the 
programme. In collaboration with the appropriate work package leaders, social 
scientists will develop and pilot a novel evaluative methodology. This will be based 
on recent advances at the intersection of Science and Technology Studies and 
Innovation Studies. In practice it will involve the commissioning of a review of 
evaluative methods in line with the principles of RRI followed by a collaboration 
with the FCT in Portugal, the current work package leaders for the development of 
indicators for ERA CoBioTech.
In 2014, the European Commission commissioned an expert group to advise on 
options for RRI indicators. The report (EC 2015) recommends the use of a limited 
set of indicators that are highly contextual, tailored to the needs and goals of the 
particular programme/project to ensure that they are both relevant and manageable. 
The expert group conclude that it was not possible for them to provide a general list 
of indicators for RRI, and that national and regional actors (including universities, 
research centres and funding agencies) need to design their own processes tailoring 
the indicators proposed in the report as well as adding their own where relevant87. 
Building on this advice, ERA CoBioTech will take the opportunity to pioneer the 
development of indicators that fuse evaluation of RRI with other forms of evaluation 
and measurement of the respective projects. The purpose of this would be to 
broaden the way programmes are measured to include measurements of the success 
of projects working in a mode consistent with the agenda outlined above. There is 
an opportunity for ERA CoBioTech to take the lead in developing indicators for the 
programme in line with its RRI agenda, and to begin to ask questions about how best 
to evaluate the programme in line with the principles of RRI outlined above. The key 
difference between this kind of approach to developing indicators and the approach 
suggested by the European Commission expert group's report is to develop a method 
of evaluation that does not evaluate RRI as separate component, but as integral to 
the programme itself87.
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Annex 1: Methodology for desk-review
To develop useable guidance for the implementation of responsible innovation in the 
context of the ERA CoBioTech Programme we used a mix of qualitative document 
analysis and qualitative interviewing. The first stage of research aimed to consolidate 
existing empirical work around Responsible Research and Innovation. We therefore 
reviewed existing policy approaches to Responsible Research and Innovation at 
the programme level, including complementary approaches for aligning social and 
scientific trajectories such as public value mapping or emerging portfolio  
analysis techniques.
Documentary analysis of published accounts working in Responsible Research and 
Innovation and interdisciplinary settings 69,70, 88-93, and two rounds of interviews 
(conducted by phone or Skype) followed the desk review. The first round of 
interviews was conducted with social scientists with experience implementing RRI 
at programme level. The purpose of these interviews was to derive cross cutting 
lessons from their experiences of implementing RRI in a range of flagship RRI 
programmes. This kind of synthesis of cross-programme experience did not to our 
knowledge exist in the published literature. We conducted a total of 6 interviews 
with social scientists who had been involved in 7 different programmes. These 
interviews were supplemented by a series of 20 similar interviews conducted by 
Smith and collaborators at GenØk, Tromsø (Dr Michael Bernstein) and the Institute 
for Advanced Sustainability Studies, Potsdam (Dr Stefan Schäfer), funded by 
the Virtual Institute for Responsible Innovation. The lessons derived from these 
interviews together with analysis of accompanying grey literature were delivered 
to ERA CoBioTech funders for comment and then subsequently integrated into the 
present document. They also form the basis of our recommendations presented in 
this document.
The second round of interviews was conducted with representatives of the funding 
bodies who are involved in ERA CoBioTech. We felt strongly that it was important 
to hear the views and experiences of funding agencies of the ERA CoBioTech for 
two reasons. First, there are significant differences amongst funders within ERA 
CoBioTech, in aspects such as organisational remits, national agenda setting 
processes, academic communities, policies regarding intellectual property, and 
mechanisms for public engagement. One of the goals for these interviews was 
therefore to learn more about how the different agencies were organised, how they 
operate and how they sit within their respective national landscapes, in order to 
develop an approach to RRI that accommodates the diversity of different national 
funders and contexts. The best way to gain this understanding was to speak directly 
to those who represent the various funding agencies for ERA CoBioTech. Second, 
it was important to include representatives of the various funding agencies to 
ensure our recommendations accommodated this diversity, and to function as 
cross-cutting recommendations. One goal of the ERA-NETs is to share expertise 
across national funding bodies and to develop shared processes for multinational 
collaboration. In our view, building this kind of bottom-up recommendations for a 
jointly funded programme, would not be possible without considering the views of 
the representatives for the programme from the different funding agencies.  
In addition to policy review and qualitative interviewing, we conducted a portfolio 
analysis of the first ERA CoBioTech call. The purpose of this analysis was twofold: 
First to examine the framing and content of Responsible Research and Innovation 
within the first round of projects; second to investigate potential complementarity 
for future capacity building activities.
The findings of the research underpinning this agenda were presented and reviewed 
in May 2018 as part of an ERA CoBioTech consortium meeting at the French National 
Research Agency (ANR), Paris.
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Annex 2: Supporting documents for ERA CoBioTech calls 
Call pre-announcement
In the pre-call announcement, the high-level description contains reference to  
RRI, e.g.:
  As with previous funding calls, all projects will be expected to include 
aspects relating to ‘Responsible Research & Innovation’, communication 
and public engagement, and data management. Further information to 
support this process is available from the relevant national parties.
Call announcement and information for evaluators
In addition to these significant portions of text, it is also important to note slight 
variations in wording that are in line with best-practice RRI, including:
  Demonstrate and discuss the implications of a developing  
bioeconomy, rather than ‘highlight’: the benefits are neither clear  
nor evenly distributed.
  Emphasising that ‘non-commercial’ partners (and therefore multiple 
models of innovation) are also possible:  
o “Partnerships between academic researchers, and commercial (e.g. 
industrial) and non-academic partners”
Scope of the joint call
Contains reference to RRI:
“ERA CoBioTech has made a commitment to ensure that the 
programme is in line with the concept of ‘Responsible Research & 
Innovation’. This is to ensure that the programme develops in ways 
that address meaningful societal demands and foster environmental 
sustainability and social justice. As part of this commitment, 
projects must 'build-in’ investigation of the social, environmental, 
philosophical or political dimensions of their research. This may 
include, but is not limited to, collaborative work with partners outside 
the natural sciences and engineering.”
Amends reference to communication to be in line with RRI and allow for 
participants to include RRI components within this part of the project:
“Each full proposal must include a two-page Dissemination and 
Communication plan, detailing how two-way dialogue with different 
public and stakeholder groups will be pursued. For more information 
see ANNEX 4: Dissemination and communication).”
Evaluation procedure
We have streamlined and clarified the evaluation criteria, removing separate 
references to LCA, RRI and ELSA and integrating them into RRI. Note that RRI should 
also be included under quality and efficiency of the implementation.
Full proposal evaluation 
Full proposals that are submitted correctly and within the deadline will be checked 
for eligibility. The eligibility check will focus on the “General Eligibility criteria” (see 
page 9) and “National or regional regulations, national of regional eligibility criteria” 
(see ANNEX 2: National or regional regulations, National or regional eligibility 
criteria”). Non-eligible proposals will result in rejection of the entire project.
The eligible proposals will be peer-review evaluated by an international panel 
of experts with relevant expertise in the scientific fields concerned. Each expert 
is independent of any funding organisation involved in this call and no Conflict 
of Interest will exist in relation to the proposals evaluated. Each proposal will be 
reviewed by at least three external reviewers/experts. The composition of the 
international evaluation panel is decided by the ERA CoBioTech Call  
Steering Committee.
Proposals will be evaluated according to the evaluation criteria  
given below:
Excellence
  Clarity and pertinence of the objectives
  Soundness of the concept
  Credibility of the proposed methodology
  Quality and expertise of the consortium as a whole
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Impact
Extent to which the outputs of the project will contribute to:
  Technological and economic development, by describing an envisioned plan to 
achieve a higher TRL of the processes and technologies (please refer to Annex X of 
this document)
  Non-academic and commercial partners, for instance through technological 
innovation and expanding exploitation capabilities of industrial partners, or 
involving users.
  Future sustainability of biotechnology research and its outcomes, supported by a 
data management (DM) plan (please refer to Call annex, below of this document)
  ERA CoBioTech’s commitment to Responsible Research  
and Innovation, for instance through investigation and consideration of:
o The environmental aspects of transformation to a bio-based economy (e.g. 
through Life Cycle Assessment); and / or,
o Interdisciplinary collaboration with social sciences and/or humanities 
researchers; and/or,
o Other innovative approaches to responsible innovation within the CoBioTech 
Programme (please refer to Annex X of this document).
  Engagement with diverse public and stakeholder groups, through an  
efficient Dissemination and Communication plan (please refer to Annex X of  
this document)
Quality and efficiency of the implementation
  Quality and effectiveness of the work plan, including extent to which the 
resources assigned to work packages are in line with their objectives  
and deliverables,
  Appropriateness of the management structures and procedures, including risk 
and innovation management,
  Complementarity of the participants and extent to which the consortium as a 
whole brings together the necessary expertise,
  Appropriateness of the allocation of tasks, ensuring that all participants have a 
valid role and adequate resources in the project to fulfil that role
  the project budget is appropriate to the planned work and allows the achievement 
of the project goals.
National Guidelines
Should provide clear indication of national/regional funder abilities to support 
different forms of RRI.
Proposal Template
Now contains clear reference to RRI through consolidation of ELSA, LCA and RRI, 
and delineation of ‘Ethics’ from ‘RRI’.
RESPONSIBLE RESEARCH & INNOVATION
Projects must demonstrate a commitment to investigating and 
addressing social, ethical, political, environmental or cultural 
dimensions of the proposed research. This may include (but is 
not limited to) collaboration with social sciences, environmental 
sciences or humanities scholars, and/or the adoption of assessment 
methodologies such as life cycle assessment, technology 
assessment, integrated assessment or sustainability assessment.
Please explain the approach you will take, how it is tailored to your 
project and how it will resourced appropriately.Comments: (max. 
2,000 characters incl. space)
Call Annex (Reviewer and applicants): Responsible Research and Innovation
The successful technologies and innovations that ERA CoBioTech aims to produce 
will need to be more than just technical: they will be successfully embedded into 
social, environmental and political worlds. This means that they will have to be a 
part of social change. There is much evidence to suggest that it is challenging to 
predict exactly how such change comes about. Instead of attempting to address 
these questions after a technology is rolled out, it is sensible to try to ‘design-
in’ consideration of the social, environmental, economic, political and cultural 
dimensions to technologies as they are being conceived, designed and tested.
If this process of ‘innovation governance’ is done well, ERA CoBioTech can help to 
produce new scientific knowledge, new technologies and innovations that are more 
democratic, more environmentally sustainable and that address more meaningful 
societal demands than may otherwise be the case. If such technologies and 
innovations actively design-in the insights and knowledge of public and stakeholder 
groups, they are more likely to be ‘socially robust’ because they will accommodate 
questions that may arise later in their development. 
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There are many forms of ‘innovation governance’ but the most prominent, and 
arguably best-developed, is ‘Responsible Research and Innovation’. There are many 
national and transnational frameworks for Responsible Research and Innovation, 
but it is these broad goals of producing more useful, more thoughtful and more 
democratic innovations that are most important to follow.
Implementing Responsible Research and Innovation requires a multi-level approach 
that is attentive to different sites of innovation governance – universities, companies, 
policy arenas. This means that responsibility must be a collective one; researchers 
are not the only ones responsible for developing innovations. ERA CoBioTech 
acknowledges this and is working to develop programme-level mechanisms for 
Responsible Research and Innovation.
At the project level this call supports a wide range of methodologies that will 
investigate the social, environmental, political, regulatory, historical, ethical or 
cultural dimensions of such research. ERA CoBioTech is conscious of the fact that 
technologies and innovation are products of social processes, meaning that attention 
may be best directed towards the laboratory, project or institutional cultures that 
produce them. Consortia should develop an approach that is best-suited to their topic 
and available expertise. The following approaches may be particularly appropriate to 
this call.
Interdisciplinary collaboration. 
Social sciences and humanities scholars may be interested in collaborating with 
you. Researchers in Science and Technology Studies, Sociology, Anthropology, 
Geography, Socio-legal studies, History, Environmental Studies, and others may 
each bring new insights and expertise to the questions raised by your project. Their 
research may focus on the social and political dimensions of the project. These may 
include, but are not limited to, questions about translational pathways, dual-use, 
interdisciplinarity, biosafety, biosecurity, intellectual property or changing cultures 
of work in the life sciences. Some of the most innovative and productive research in 
this space has attempted to build collaborative research endeavours that value the 
contributions of both the social and natural sciences, for instance by creating spaces 
for reflection and discussion informed by data from each discipline.
Life Cycle Assessment (LCA) 
LCA is an internationally standardised methodology (ISO 14040: 2006) that helps 
to quantify the environmental pressures related to goods and services (products). 
By attempting to account for the full life-cycle of the product, LCA helps to identify 
the trade-offs and potential areas for improvement . The applicants in this ERA 
CoBioTech call may use and are encouraged to seek to advance the development 
of LCA or another robust methodology to assess the environmental implications of 
products, processes and technologies that may be developed or improved within  
the project.
Other forms of assessment  
Environmental aspects are only one dimension of products, processes and 
technologies in development; other aspects can be assessed through tools beyond 
LCA. There are many well-established methodologies, including but not limited to: 
foresight studies; real time technology assessment; value sensitive design; user-
driven design; critical design; techno-moral vignettes; citizen forums; co-production 
research; integrated assessment; alternatives assessment; multi-criteria mapping; 
socio-technical integration research; and a wide range of approaches within 
History and Philosophy of Science and Technology, Innovation Studies, Science and 
Technology Studies, Sustainability Science or Empirical Bioethics.
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Core questions and assumptions
  What is the central idea of your project?
  Are there any assumptions that underpin it and that would affect its success?
  Are there any kinds of knowledge that would help address those assumptions?
  Does your university or organisation have researchers working on the social, 
political, ethical or environmental dimensions of the life sciences?
Integration
  Is it possible to develop a set of shared research questions for all your 
collaborators at the outset?
  Does the most important question revolve around research in the lab or some 
other site (such as the pathways for translation, regulation, or the environment)?
  Are there particular points in time or sites where input and exchange would be 
particularly valuable?
  Is it valuable for the RRI component to extend over the life of your project?
  Is it possible for insights from the social, environmental, or legal research to 
inform the outcomes of your project? Can you demonstrate this?
Support & flexibility
  Can you demonstrate that the RRI research is resourced appropriately?
  Are there any extra resources, such as travel and networking, that you require 
from the ERA CoBioTech programme to support your RRI project?
  Is it possible for your consortia proposal to adapt to changing developments 
within the project over time?
Questions to consider when developing your consortia proposal
The following questions may be helpful to consider when developing your proposal.
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Call pre-announcement
In the pre-call announcement, the high-level description contains reference to RRI, e.g.:
  Check the call scope and project topic areas   Build a consortium (ERA CoBioTech partnering tool:  
www.submission-cobiotech.eu)
  Think about what each partner would offer, and discuss what 
each wants to offer.
  Ensure that you have appropriate expertise for the different 
features of the call, including Responsible Research & Innovation.
  Check carefully:
  the general eligibility criteria and principles of  
the ERA CoBioTech call
  The National Regulations of all consortium partners
  Develop an appropriate plan for dissemination 
of the results and discussion with relevant 
public, stakeholder or expert groups in 
accordance to the guidelines of ERA CoBioTech 
(Annex 4 of the Call Announcement) 
  Select an appropriate DM approach and create a data 
management  plan according to the requirements of ERA 
CoBioTech (See Call Documents)  
  Create a  plan how to achieve a higher TRL (TRL 
Plan) including , when relevant, exploitation and 
commercialisation of the project results
  Complete your full proposal according to the 
requirements in call text.
  The project description should not exceed 
max. 20 pages
  Submit your proposal via CoBioTech submission system: 
www.submission-cobiotech.eu before the deadline
  it is possible to submit your proposal several times – old  
version will be replaced by new version
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